Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with valsartan or valsartan plus HCTZ for 34 weeks with or without respective measures

Next Previous
X
Search
Trial Profile

A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with valsartan or valsartan plus HCTZ for 34 weeks with or without respective measures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valsartan (Primary) ; Valsartan/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms VALIDATE
  • Sponsors Novartis

    • Most Recent Events

    • 07 Nov 2011 Additional location (Germany) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Actual end date (June 2007) added as reported by ClinicalTrials.gov.
    • 07 Nov 2007 Status changed from in progress to completed

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top